STIC Search Report
EIC 1700

STIC Database Tracking Number: 195114

TO: Ben Sackey
Location: REM 5B31
Art Unit : 1626
July 12, 2006

Case Serial Number: 10/790647

From: Kathleen Fuller
Location: EIC 1700
REMSEN 4B28
Phone: 571/272-2505
Kathleen.Fuller@uspto.gov

Search Notes

506 structures from claim structure –only 3 CA references all to the applicants.

Search and Information Resources Administration

FOR OFFICIAL USE ONLY

ACCESS DB # 195114

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: BEN SACKEY Examiner #: 73489 Date: 7/10/06

Art Unit: 1626 Phone Number: 2-1704 Serial Number: 10/798,697 ~~10/798,697~~ ~~10/790,647~~

Location (Bldg/Room#): Rem 5B31 (Mailbox #): _____ Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Novel heterocyclic Compds, their prep, pharm containing them

Inventors (please provide full names): Takeuchi et al.

Earliest Priority Date: 7/26/01

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

SCIENTIFIC REFERENCE BR
Sci. & Tech. Info. Ctr.
JUL 1
Pat. & T.M. Office

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



R^1 – R^4 are H, halo, OH, S, NH_2, CN etc.
$CONH_2$, $SONH_2$, SO_2NHMe etc.

or

R^2 and R^3 may form 5- 6 membered ring

n is 1–8

W is O, S, NR^9 where R^9 is H, C_{1-2}alkyl or acyl.

A is aromatic het or heterocyclic group

R^5 and R^6 are H, OH, alkyl, halo

Y is O, S

Z is O, S

thanks

=> FILE REG
FILE 'REGISTRY' ENTERED AT 14:38:45 ON 12 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5
DICTIONARY FILE UPDATES: 11 JUL 2006 HIGHEST RN 892124-43-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> FILE HCAPLU
FILE 'HCAPLUS' ENTERED AT 14:38:52 ON 12 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 12 Jul 2006 VOL 145 ISS 3
FILE LAST UPDATED: 11 Jul 2006 (20060711/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> D QUE L8
L1 1 SEA FILE=HCAPLUS ABB=ON US2004-790647/AP
L3 STR



N @16

506 structures from query

REP G1=(1-10) CH2
VAR G2=O/S/N
VAR G3=O/S
VAR G4=O/N/S/16
NODE ATTRIBUTES:
NSPEC IS R AT 16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE
L5 506 SEA FILE=REGISTRY SSS FUL L3
L7 3 SEA FILE=HCAPLUS ABB=ON L5
L8 1 SEA FILE=HCAPLUS ABB=ON L1 AND L7

3 CA references

applicant with many compound printed only 1 structure

=> D L8 BIB ABS IND FHITSTR

L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:1007858 HCAPLUS
DN 140:59512
TI Preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity
IN Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Barot, Vijay Kumar Gajubhai; Raval, Saurin Khimshanker; Raval, Preeti Saurin; Basu, Sujay
PA Cadilla Healthcare Limited, India
SO U.S. Pat. Appl. Publ., 116 pp., Cont.-in-part of U.S. Pat. Appl. 2003 199,498.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003236254	A1	20031225	US 2002-200107	20020719
	US 7041837	B2	20060509		
	US 2003199498	A1	20031023	US 2001-928242	20010810
	US 6987123	B2	20060117		

US 2004186099 A1 20040923 US 2004-790647 20040301 <--
PRAI IN 2001-MU711 A 20010726
US 2001-928242 A2 20010810
OS MARPAT 140:59512
GI



I

AB Title compds. [I; R1-R4 = H, haloalkyl, NO2, cyano, CHO, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, aralkyl, heterocyclyl, heteroaryl, etc.; W = O, S, NR9; R9 = H, alkyl, aryl; Ar = (substituted) aryl, heteroaryl; R5, R6 = H, OH, alkyl, etc.; R5R6 = bond; X = O, S; R7 = H, perfluoroalkyl, (substituted) alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, acyl, etc.; R8 = H, (substituted) alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, etc.; Y = O, S; Z = O, S, NR10; R10 = H, (substituted) alkyl, aryl, aralkyl, hydroxyalkyl, aminoalkyl, heteroaryl, etc.; R8R10 = atoms to form a (substituted) 5-6 membered ring; n = 2], were prepared Thus, Me 2-ethoxy-3-[6-[2-[2-(4-methoxyphenyl)-5-methylpyrrol-1-yl]ethoxy]naphthalen-2-yl]propanoate (preparation given) at 3 mg/kg day orally in mice reduced triglycerides by 26%. I may be useful in the treatment of obesity, hyperlipidemia, hypercholesteremia, syndrome X and diabetes. Pharmaceutical composition comprising the compound I is claimed.

IC ICM A61K031-541
ICS A61K031-5377; A61K031-496; A61K031-454; A61K031-4439; A61K031-4025; C07D417-02; C07D413-02; C07D043-02
INCL 514227800; X51-425.401; X51-423.55; X51-432.6; X51-440.8; X51-442.2; X54-46.0; X54-414.1; X54-437.2; X54-420.8
CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63
ST pyrrolylethoxyphenylethoxypropanoate prepn hypolipemic anticholesteremic; obesity hyperlipidemia hypercholesteremia diabetes treatment pyrrolylethoxyphenylethoxypropanoate prepn
IT Antiarteriosclerotics
(antiatherosclerotics; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Diabetes mellitus
(complications treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Artery, disease
(coronary, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Mental and behavioral disorders
(dementia, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Kidney, disease
(diabetic nephropathy, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Eye, disease
(diabetic retinopathy, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Blood vessel, disease
(endothelium, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Kidney, disease
(failure, chronic, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Inflammation
Kidney, disease
(glomerulonephritis, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Kidney, disease
(glomerulosclerosis, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT High-density lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(increasers; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Intestine, disease
(inflammatory, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Metabolic disorders
(metabolic syndrome X, treatment of; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Albumins, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(microalbuminuria, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Muscular dystrophy
(myotonic, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Kidney, disease
(nephrosclerosis, hypertensive nephroslcerosis treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Kidney, disease
(nephrotic syndrome, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Diabetes mellitus
(non-insulin-dependent, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Inflammation
Pancreas, disease
(pancreatitis, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Ovary, disease
(polycystic, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Anti-inflammatory agents
Antiarteriosclerotics
Anticholesteremic agents
Antidiabetic agents
Antihypertensives
Antiobesity agents
Antitumor agents

Cardiovascular agents
Cognition enhancers
Human
Hypolipemic agents
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Low-density lipoproteins
Very-low-density lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reducers; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Fatty acids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reducing free fatty acids; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Glycerides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reducing plasma triglycerides; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Osteoporosis
(treatment with antiosteoporotics; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Arteriosclerosis
Atherosclerosis
Cardiovascular system, disease
Hypercholesterolemia
Hyperglycemia
Hypertension
Kidney, disease
Neoplasm
Obesity
Psoriasis
Xanthomatosis
(treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Dyslipidemia
Hyperlipidemia
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Endothelium
(vascular, disease, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT **494848-08-7P 494848-09-8P 494848-10-1P**
494848-11-2P 494848-12-3P 494848-13-4P
494848-14-5P 494848-15-6P 494848-16-7P
494848-17-8P 494848-18-9P 494848-19-0P
494848-20-3P 494848-21-4P 494848-22-5P
494848-24-7P 494848-25-8P 494848-27-0P
494848-28-1P 494848-29-2P 494848-30-5P
494848-31-6P 494848-32-7P 494848-33-8P
494848-34-9P 494848-35-0P 494848-36-1P
494848-37-2P 494848-38-3P 494848-39-4P
494848-40-7P 494848-41-8P 494848-42-9P
494848-43-0P 494848-44-1P 494848-45-2P
494848-46-3P 494848-47-4P 494848-48-5P
494848-49-6P 494848-50-9P 494848-51-0P
494848-52-1P 494848-53-2P 494848-54-3P
494848-55-4P 494848-56-5P 494848-57-6P

494848-58-7P 494848-59-8P 494848-60-1P
494848-61-2P 494848-62-3P 494848-63-4P
494848-64-5P 494848-65-6P 494848-66-7P
494848-67-8P 494848-68-9P 494848-69-0P
494848-70-3P 494848-71-4P 494848-72-5P 494848-73-6P
494848-74-7P 494848-76-9P 494848-77-0P
494848-79-2P 494848-81-6P 494848-82-7P
494848-84-9P 494848-86-1P 494848-88-3P
494848-90-7P 494848-92-9P 494848-94-1P
494848-96-3P 494848-98-5P 494849-00-2P
494849-01-3P 494849-02-4P 494849-03-5P
494849-04-6P 494849-05-7P 494849-06-8P
494849-07-9P 494849-08-0P 494849-09-1P
494849-10-4P 494849-11-5P 494849-12-6P
494849-13-7P 494849-14-8P 494849-15-9P
494849-16-0P 494849-17-1P 494849-18-2P
494849-19-3P 494849-20-6P 494849-21-7P
494849-22-8P 494849-23-9P 494849-24-0P
494849-25-1P 494849-26-2P 494849-27-3P
494849-28-4P 494849-29-5P 494849-30-8P
494849-31-9P 494849-32-0P 494849-33-1P
494849-34-2P 494849-35-3P 494849-36-4P
494849-37-5P 494849-38-6P 494849-39-7P
494849-40-0P 494849-41-1P 494849-42-2P
494849-43-3P 494849-44-4P 494849-45-5P
494849-46-6P 494849-47-7P 494849-48-8P
494849-49-9P 494849-50-2P 494849-51-3P
494849-52-4P 494849-53-5P 494849-54-6P
494849-55-7P 494849-56-8P 494849-57-9P
494849-58-0P 494849-59-1P 494849-60-4P
494849-61-5P 494849-62-6P 494849-63-7P
494849-64-8P 494849-65-9P 494849-66-0P
494849-67-1P 494849-68-2P 494849-69-3P
494849-70-6P 494849-71-7P 494849-72-8P
494849-73-9P 494849-74-0P 494849-75-1P
494849-76-2P 494849-77-3P 494849-78-4P
494849-79-5P 494849-80-8P 494849-81-9P 494849-82-0P
494849-83-1P 494849-84-2P 494849-85-3P
494849-86-4P 494849-87-5P 494849-88-6P
494849-89-7P 494849-90-0P 494849-91-1P
494849-92-2P 494849-93-3P 494849-94-4P
494849-95-5P 494849-96-6P 494849-97-7P
494849-98-8P 494849-99-9P 494850-00-9P
494850-01-0P 494850-02-1P 494850-03-2P
494850-04-3P 494850-05-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of pyrrolylethoxyphenylethoxypropanoates having
hypolipidemic and hypocholesteremic activity)

IT 50-78-2, Aspirin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 50-99-7, D-Glucose, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(impaired glucose tolerance treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 83-46-5, β-Sitosterol 9028-35-7, HMG-CoA reductase 11128-99-7, Angiotensin II 74315-95-0, α-Glycosidase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, coadministration; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 169494-85-3, Leptin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(leptin resistance treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 351426-18-1P 351426-19-2P 351426-20-5P **351426-21-6P**
351426-22-7P 351426-23-8P 351426-24-9P
351426-25-0P 351426-26-1P 351426-27-2P
351426-28-3P 351426-29-4P 351426-30-7P
351426-31-8P 351426-32-9P 351426-33-0P
351426-34-1P 351426-35-2P 351426-36-3P 351426-37-4P
351426-38-5P 351426-39-6P 351426-40-9P **351426-41-0P**
351426-42-1P 351426-43-2P 351426-44-3P
351426-45-4P 351426-46-5P 351426-47-6P
351426-48-7P 351426-49-8P 351426-50-1P 351426-51-2P
351426-52-3P **351426-53-4P 351426-54-5P**
351426-55-6P 351426-56-7P 351426-57-8P
351426-58-9P 351426-59-0P 351426-60-3P
351426-61-4P 351426-62-5P 351426-63-6P
351426-64-7P 351426-65-8P 351426-66-9P
351426-67-0P 351426-68-1P 351426-69-2P 351426-70-5P
351426-71-6P 351426-72-7P 351426-73-8P **351426-74-9P**
351426-75-0P 351426-76-1P 351426-78-3P
351426-79-4P 351427-20-8P **494851-13-7P**
494851-14-8P 494851-15-9P 494851-16-0P
494851-17-1P 494851-18-2P 494851-19-3P
494851-20-6P 494851-21-7P 494851-22-8P
494851-23-9P 494851-24-0P 494851-25-1P
494851-26-2P 494851-27-3P 494851-28-4P
494851-29-5P 494851-30-8P **494851-31-9P**
494851-32-0P 494851-33-1P 494851-34-2P
494851-35-3P **494851-36-4P 494851-37-5P 494851-38-6P 494851-39-7P 494851-40-0P 494851-41-1P**
494851-42-2P 494851-43-3P 494851-44-4P
494851-45-5P 494851-46-6P 494851-47-7P
494851-48-8P 494851-49-9P 494851-50-2P
494851-51-3P 494851-52-4P 494851-53-5P
494851-54-6P 494851-55-7P 494851-56-8P
494851-57-9P 494851-58-0P 494851-59-1P
494851-60-4P 494851-61-5P 494851-62-6P
494851-63-7P 494851-64-8P 494851-65-9P
494851-66-0P 494851-67-1P **494851-68-2P**
494851-69-3P 494851-70-6P 494851-71-7P
494851-72-8P 494851-73-9P 494851-74-0P
494851-75-1P 494851-76-2P 494851-78-4P
494851-79-5P 494851-80-8P 494851-81-9P
494851-82-0P 494851-83-1P 494851-84-2P
494851-85-3P 494851-86-4P 494851-87-5P
494851-88-6P 494851-89-7P 494851-90-0P
494851-91-1P 494851-92-2P 494851-93-3P
494851-94-4P 494851-95-5P 494851-96-6P
494851-97-7P 494851-99-9P 494852-00-5P
494852-01-6P 494852-02-7P 494852-03-8P
495398-86-2P 495398-87-3P 495398-88-4P
495398-89-5P 495398-90-8P 495398-91-9P
495398-92-0P 495398-93-1P 495398-94-2P

495398-95-3P 495398-96-4P 495398-97-5P
495398-98-6P 495398-99-7P 495399-00-3P
495399-01-4P 495399-02-5P 495399-03-6P
495399-04-7P 495399-05-8P 495399-06-9P
495399-07-0P 495399-08-1P 495399-09-2P
495399-10-5P 495399-11-6P 495399-12-7P
495399-13-8P 495399-14-9P 495399-15-0P
495399-16-1P 495399-17-2P 495399-18-3P
495399-19-4P 495399-20-7P 495399-21-8P
495399-22-9P 495399-23-0P 495399-24-1P
495399-25-2P 495399-26-3P 495399-27-4P
495399-28-5P 495399-29-6P 495399-30-9P
495399-31-0P 495399-32-1P 495399-33-2P
495399-34-3P 495399-35-4P 495399-36-5P
495399-37-6P 495399-38-7P 495399-55-8P
638195-89-8P 638195-90-1P 638195-91-2P 638195-92-3P
638195-93-4P 638195-94-5P 638195-95-6P
638195-96-7P 638195-97-8P 638195-98-9P
638195-99-0P 638196-00-6P 638196-01-7P
638196-02-8P 638196-03-9P 638196-04-0P
638196-05-1P 638196-06-2P 638196-07-3P
638196-08-4P 638196-09-5P 638196-10-8P
638196-11-9P 638196-12-0P 638196-13-1P
638196-14-2P 638196-15-3P 638196-16-4P
638196-17-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 638196-18-6P 638196-19-7P 638196-20-0P
638196-21-1P 638196-22-2P 638196-23-3P
638196-24-4P 638196-25-5P 638196-26-6P
638196-27-7P 638196-28-8P 638196-29-9P
638196-30-2P 638196-31-3P 638196-32-4P
638196-33-5P 638196-34-6P 638196-35-7P 638196-36-8P
638196-37-9P 638196-38-0P 638196-39-1P
638196-40-4P 638196-41-5P 638196-42-6P
638196-43-7P 638196-44-8P 638196-45-9P 638196-46-0P
638196-47-1P 638196-48-2P 638196-49-3P
638196-50-6P 638196-51-7P 638196-52-8P
638196-53-9P 638196-54-0P 638196-55-1P
638196-56-2P 638196-57-3P 638196-58-4P 638196-59-5P
638196-60-8P 638196-61-9P 638196-62-0P
638196-63-1P 638196-64-2P 638196-65-3P
638196-66-4P 638196-67-5P 638196-68-6P
638196-69-7P 638196-70-0P 638196-71-1P
638196-72-2P 638196-73-3P 638196-74-4P
638196-75-5P 638196-76-6P 638196-77-7P
638196-79-9P 638196-80-2P 638196-81-3P
638196-82-4P 638196-83-5P 638196-84-6P
638196-85-7P 638196-86-8P 638196-87-9P
638196-88-0P 638196-89-1P 638196-90-4P
638196-91-5P 638196-92-6P 638196-93-7P
638196-94-8P 638196-95-9P 638196-96-0P
638196-97-1P 638196-98-2P 638196-99-3P
638197-00-9P 638197-01-0P 638197-02-1P
638197-03-2P 638197-04-3P 638197-05-4P
638197-06-5P 638197-07-6P 638197-08-7P
638197-09-8P 638197-10-1P 638197-11-2P

638197-12-3P 638197-13-4P 638197-14-5P
638197-15-6P 638197-16-7P **638197-17-8P 638197-18-9P**
638197-19-0P 638197-20-3P 638197-21-4P
638197-22-5P 638197-23-6P 638197-24-7P
638197-25-8P 638197-26-9P 638197-27-0P
638197-28-1P 638197-29-2P 638197-30-5P
638197-31-6P 638197-32-7P 638197-33-8P
638197-34-9P 638197-35-0P 638197-36-1P
638197-37-2P 638197-38-3P 638197-39-4P 638197-40-7P
638197-41-8P 638197-42-9P 638197-43-0P
638197-44-1P 638197-45-2P 638197-46-3P
638197-47-4P 638197-48-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 105-36-2, Ethyl bromoacetate 106-93-4, 1,2-Dibromoethane 107-21-1, Ethylene glycol, reactions 123-08-0, 4-Hydroxybenzaldehyde 141-43-5, Ethanolamine, reactions 1003-29-8, 2-Formylpyrrole 4437-46-1, 1-Phenylhexane-1,4-dione 13676-06-7, Triethyl 2-ethoxyphosphonoacetate 53391-61-0, 2-Methylthiopyrrole 197299-16-4, Ethyl 3-(4-hydroxyphenyl)-2-ethoxypropionate 222555-06-8, Ethyl (S)-3-(4-hydroxyphenyl)-2-ethoxypropionate 267228-43-3, Methyl (S)-3-(4-hydroxyphenyl)-2-methoxypropionate 494852-05-0 494852-06-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 6719-02-4P, 1H-Pyrrole-1-ethanol 23461-34-9P 50524-76-0P 83662-06-0P 85801-32-7P 93617-01-7P 100371-84-4P 321742-49-8P 351426-82-9P
351426-83-0P 351426-84-1P 351426-85-2P 351426-86-3P 351426-88-5P
351426-89-6P 351426-90-9P 351426-91-0P 351426-92-1P 351426-93-2P
351426-94-3P 351426-95-4P 351426-96-5P 351426-98-7P 351426-99-8P
351427-00-4P 400715-78-8P 494850-06-5P 494850-07-6P 494850-08-7P
494850-09-8P 494850-10-1P 494850-11-2P 494850-12-3P 494850-13-4P
494850-14-5P 494850-15-6P 494850-16-7P 494850-17-8P 494850-18-9P
494850-19-0P 494850-20-3P 494850-21-4P 494850-22-5P 494850-23-6P
494850-24-7P 494850-25-8P 494850-26-9P 494850-27-0P 494850-28-1P
494850-29-2P 494850-30-5P 494850-31-6P 494850-32-7P 494850-33-8P
494850-34-9P 494850-35-0P 494850-36-1P 494850-37-2P 494850-38-3P
494850-39-4P 494850-40-7P 494850-41-8P 494850-42-9P 494850-43-0P
494850-44-1P 494850-45-2P 494850-46-3P 494850-47-4P 494850-48-5P
494850-49-6P 494850-50-9P 494850-51-0P 494850-52-1P 494850-53-2P
494850-54-3P 494850-55-4P 494850-56-5P 494850-57-6P 494850-58-7P
494850-59-8P 494850-60-1P 494850-61-2P 494850-62-3P 494850-63-4P
494850-65-6P 494850-66-7P 494850-67-8P 494850-68-9P 494850-69-0P
494850-70-3P 494850-71-4P 494850-72-5P 494850-73-6P 494850-74-7P
494850-75-8P 494850-76-9P 494850-77-0P 494850-78-1P 494850-79-2P
494850-80-5P 494850-81-6P 494850-82-7P 494850-83-8P 494850-84-9P
494850-85-0P 494850-86-1P 494850-87-2P 494850-88-3P 494850-89-4P
494850-90-7P 494850-91-8P 494850-92-9P 494850-93-0P 494850-94-1P
494850-95-2P 494850-96-3P 494850-97-4P 494850-98-5P 494850-99-6P
494851-00-2P 494851-01-3P 494851-02-4P 494851-03-5P 494851-04-6P
494851-05-7P 494851-06-8P 494851-07-9P 494851-08-0P 494851-09-1P
494851-10-4P 494851-11-5P 494851-12-6P 494852-04-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 59-67-6, Nicotinic acid, biological studies 9004-10-8, Insulin,

biological studies 11041-12-6, Cholestyramine 23288-49-5, Probucol 50925-79-6, Cholestipol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT **494848-08-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of pyrrolylethoxyphenylethoxypropanoates having
hypolipidemic and hypocholesteremic activity)

RN 494848-08-7 HCAPLUS

CN Benzenepropanamide, α-ethoxy-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-(2-methyl-5-phenyl-1H-pyrrol-1-yl)ethoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> D QUE
L1 1 SEA FILE=HCAPLUS ABB=ON US2004-790647/AP
L3 STR



N @16

REP G1=(1-10) CH2

```
VAR G2=O/S/N
VAR G3=O/S
VAR G4=O/N/S/16
NODE ATTRIBUTES:
NSPEC   IS R      AT  16
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  16

STEREO ATTRIBUTES: NONE
L5          506 SEA FILE=REGISTRY SSS FUL L3
L7            3 SEA FILE=HCAPLUS ABB=ON  L5
L8            1 SEA FILE=HCAPLUS ABB=ON  L1 AND L7
L9            2 SEA FILE=HCAPLUS ABB=ON  L7 NOT L8
```

Remaining 2 references

=> SEL HIT RN L9 1-2
E1 THROUGH E360 ASSIGNED

360 structures as printed only 1 structure for each

=> D L9 BIB ABS IND FHITSTR 1-2

L9 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:97297 HCAPLUS
DN 138:153432
TI Preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity.
IN Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Barot, Vijay Kumar; Raval, Saurin Khimshankar; Raval, Preeti Saurin; Basu, Sujay / applicants
PA Cadila Healthcare Limited, India
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003009841	A1	20030206	WO 2002-IN155	20020725
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2454863	AA	20030206	CA 2002-2454863	20020725
	EP 1414439	A1	20040506	EP 2002-751609	20020725
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1558758	A	20041229	CN 2002-818983	20020725
	BR 2002011665	A	20050111	BR 2002-11665	20020725
	JP 2005503367	T2	20050203	JP 2003-515234	20020725
	NO 2004000301	A	20040324	NO 2004-301	20040123
	ZA 2004000563	A	20041029	ZA 2004-563	20040126
PRAI	IN 2001-MU711	A	20010726		

WO 2002-IN155 W 20020725
OS MARPAT 138:153432
GI



I

AB Title compds. [I; R1, R4 = H, haloalkyl, NO2, cyano, CHO, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, aralkyl, heterocyclyl, heteroaryl, etc.; W = O, S, NR9; R9 = H, alkyl, aryl; Ar = (substituted) aryl, heteroaryl; R5, R6 = H; R5R6 = bond; R7 = H, perfluoroalkyl, (substituted) alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, acyl, etc.; R8 = H, (substituted) alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, etc.; Y = O, S; Z = O, S, NR10; R10 = H, (substituted) alkyl, aryl, aralkyl, hydroxyalkyl, aminoalkyl, heteroaryl, etc.; R8R10 = atoms to form a (substituted) 5-6 membered ring; n = 2], were prepared Thus, Me 2-ethoxy-3-[6-[2-[2-(4-methoxyphenyl)-5-methylpyrrol-1-yl]ethoxy]naphthalen-2-yl]propanoate (preparation given) at 3 mg/kg day orally in mice reduced triglycerides by 26%. I may be useful in the treatment of obesity, hyperlipidemia, hypercholesteremia, syndrome X and diabetes.

IC ICM A61K031-40
ICS C07D207-325; C07D207-333; C07D407-04; C07D409-04; C07D401-04; A61K031-4025; A61P003-06

CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1

ST pyrrolylethoxyphenylethoxypropanoate prepn hypolipidemic hypocholesteremic; obesity hyperlipidemia hypercholesteremia diabetes treatment pyrrolylethoxyphenylethoxypropanoate prepn

IT Diabetes mellitus
(complications treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Mental and behavioral disorders
(dementia, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Kidney, disease
(diabetic nephropathy, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Eye, disease
(diabetic retinopathy, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Blood vessel, disease
(endothelium, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Kidney, disease
(failure, chronic, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Inflammation
Kidney, disease
(glomerulonephritis, treatment; preparation of pyrrolylethoxyphenylethoxypro

panoates having hypolipidemic and hypocholesteremic activity)
IT Kidney, disease
(glomerulosclerosis, treatment; preparation of pyrrolylethoxyphenylethoxypro panoates having hypolipidemic and hypocholesteremic activity)
IT High-density lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(increasers; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Intestine, disease
(inflammatory, treatment; preparation of pyrrolylethoxyphenylethoxypropanoat es having hypolipidemic and hypocholesteremic activity)
IT Albumins, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(microalbuminuria, treatment; preparation of pyrrolylethoxyphenylethoxypropa noates having hypolipidemic and hypocholesteremic activity)
IT Muscular dystrophy
(myotonic, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Kidney, disease
(nephrosclerosis, hypertensive nephroslcerosis treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Kidney, disease
(nephrotic syndrome, treatment; preparation of pyrrolylethoxyphenylethoxypro panoates having hypolipidemic and hypocholesteremic activity)
IT Diabetes mellitus
(non-insulin-dependent, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Inflammation
Pancreas, disease
(pancreatitis, treatment; preparation of pyrrolylethoxyphenylethoxypropanoat es having hypolipidemic and hypocholesteremic activity)
IT Ovary, disease
(polycystic, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Antiarteriosclerotics
Anticholesteremic agents
Antidiabetic agents
Antiobesity agents
Antitumor agents
Cognition enhancers
Human
Hypolipemic agents
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Low-density lipoproteins
Very-low-density lipoproteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reducers; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Osteoporosis
(treatment with antiosteoporotics; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)
IT Arteriosclerosis
Cardiovascular system, disease
Hypercholesterolemia
Hyperglycemia
Kidney, disease

Neoplasm
Obesity
Psoriasis
Xanthomatosis
(treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Hyperlipidemia
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT Endothelium
(vascular, disease, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT **494848-08-7P 494848-09-8P 494848-10-1P**
494848-11-2P 494848-12-3P 494848-13-4P
494848-14-5P 494848-15-6P 494848-16-7P
494848-17-8P 494848-18-9P 494848-19-0P
494848-20-3P 494848-21-4P 494848-22-5P
494848-24-7P 494848-25-8P 494848-27-0P
494848-28-1P 494848-29-2P 494848-30-5P
494848-31-6P 494848-32-7P 494848-33-8P
494848-34-9P 494848-35-0P 494848-36-1P
494848-37-2P 494848-38-3P 494848-39-4P
494848-40-7P 494848-41-8P 494848-42-9P
494848-43-0P 494848-44-1P 494848-45-2P
494848-46-3P 494848-47-4P 494848-48-5P
494848-49-6P 494848-50-9P 494848-51-0P
494848-52-1P 494848-53-2P 494848-54-3P
494848-55-4P 494848-56-5P 494848-57-6P
494848-58-7P 494848-59-8P 494848-60-1P
494848-61-2P 494848-62-3P 494848-63-4P
494848-64-5P 494848-65-6P 494848-66-7P
494848-67-8P 494848-68-9P 494848-69-0P
494848-70-3P 494848-71-4P 494848-72-5P 494848-73-6P
494848-74-7P **494848-76-9P 494848-77-0P**
494848-79-2P 494848-81-6P 494848-82-7P
494848-84-9P 494848-86-1P 494848-88-3P
494848-90-7P 494848-92-9P 494848-94-1P
494848-96-3P 494848-98-5P 494849-00-2P
494849-01-3P 494849-02-4P 494849-03-5P
494849-04-6P 494849-05-7P 494849-06-8P
494849-07-9P 494849-08-0P 494849-09-1P
494849-10-4P 494849-11-5P 494849-12-6P
494849-13-7P 494849-14-8P 494849-15-9P
494849-16-0P 494849-17-1P 494849-18-2P
494849-19-3P 494849-20-6P 494849-21-7P
494849-22-8P 494849-23-9P 494849-24-0P
494849-25-1P 494849-26-2P 494849-27-3P
494849-28-4P 494849-29-5P 494849-30-8P
494849-31-9P 494849-32-0P 494849-33-1P
494849-34-2P 494849-35-3P 494849-36-4P
494849-37-5P 494849-38-6P 494849-39-7P
494849-40-0P 494849-41-1P 494849-42-2P
494849-43-3P 494849-44-4P 494849-45-5P
494849-46-6P 494849-47-7P 494849-48-8P
494849-49-9P 494849-50-2P 494849-51-3P
494849-52-4P 494849-53-5P 494849-54-6P
494849-55-7P 494849-56-8P 494849-57-9P
494849-58-0P 494849-59-1P 494849-60-4P
494849-61-5P 494849-62-6P 494849-63-7P

494849-64-8P 494849-65-9P 494849-66-0P
494849-67-1P 494849-68-2P 494849-69-3P
494849-70-6P 494849-71-7P 494849-72-8P
494849-73-9P 494849-74-0P 494849-75-1P
494849-76-2P 494849-77-3P 494849-78-4P
494849-79-5P 494849-80-8P 494849-81-9P **494849-82-0P**
494849-83-1P 494849-84-2P 494849-85-3P
494849-86-4P 494849-87-5P 494849-88-6P
494849-89-7P 494849-90-0P 494849-91-1P
494849-92-2P 494849-93-3P 494849-94-4P
494849-95-5P 494849-96-6P 494849-97-7P
494849-98-8P 494849-99-9P 494850-00-9P
494850-01-0P 494850-02-1P 494850-03-2P
494850-04-3P 494850-05-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of pyrrolylethoxyphenylethoxypropanoates having
hypolipidemic and hypocholesteremic activity)

IT 50-78-2, Aspirin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 50-99-7, D-Glucose, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(impaired glucose tolerance treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 83-46-5, β-Sitosterol 9028-35-7, HMG-CoA reductase 11128-99-7, Angiotensin II 74315-95-0, α-Glycosidase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors, coadministration; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 169494-85-3, Leptin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(leptin resistance treatment; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT **494851-13-7P 494851-14-8P 494851-15-9P**
494851-16-0P 494851-17-1P 494851-18-2P
494851-19-3P 494851-20-6P 494851-21-7P
494851-22-8P 494851-23-9P 494851-24-0P
494851-25-1P 494851-26-2P 494851-27-3P
494851-28-4P 494851-29-5P 494851-30-8P
494851-31-9P 494851-32-0P 494851-33-1P
494851-34-2P 494851-35-3P **494851-36-4P**
494851-37-5P 494851-38-6P 494851-39-7P
494851-40-0P 494851-41-1P 494851-42-2P
494851-43-3P 494851-44-4P 494851-45-5P
494851-46-6P 494851-47-7P 494851-48-8P
494851-49-9P 494851-50-2P 494851-51-3P
494851-52-4P 494851-53-5P 494851-54-6P
494851-55-7P 494851-56-8P 494851-57-9P
494851-58-0P 494851-59-1P 494851-60-4P
494851-61-5P 494851-62-6P 494851-63-7P
494851-64-8P 494851-65-9P 494851-66-0P
494851-67-1P **494851-68-2P 494851-69-3P**
494851-70-6P 494851-71-7P 494851-72-8P
494851-73-9P 494851-74-0P 494851-75-1P
494851-76-2P 494851-78-4P 494851-79-5P

494851-80-8P 494851-81-9P 494851-82-0P
494851-83-1P 494851-84-2P 494851-85-3P
494851-86-4P 494851-87-5P 494851-88-6P
494851-89-7P 494851-90-0P 494851-91-1P
494851-92-2P 494851-93-3P 494851-94-4P
494851-95-5P 494851-96-6P 494851-97-7P
494851-99-9P 494852-00-5P 494852-01-6P
494852-02-7P 494852-03-8P 495398-86-2P
495398-87-3P 495398-88-4P 495398-89-5P
495398-90-8P 495398-91-9P 495398-92-0P
495398-93-1P 495398-94-2P 495398-95-3P
495398-96-4P 495398-97-5P 495398-98-6P
495398-99-7P 495399-00-3P 495399-01-4P
495399-02-5P 495399-03-6P 495399-04-7P
495399-05-8P 495399-06-9P 495399-07-0P
495399-08-1P 495399-09-2P 495399-10-5P
495399-11-6P 495399-12-7P 495399-13-8P
495399-14-9P 495399-15-0P 495399-16-1P
495399-17-2P 495399-18-3P 495399-19-4P
495399-20-7P 495399-21-8P 495399-22-9P
495399-23-0P 495399-24-1P 495399-25-2P
495399-26-3P 495399-27-4P 495399-28-5P
495399-29-6P 495399-30-9P 495399-31-0P
495399-32-1P 495399-33-2P 495399-34-3P
495399-35-4P 495399-36-5P 495399-37-6P
495399-38-7P 495399-55-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 105-36-2, Ethyl bromoacetate 106-93-4, 1,2-Dibromoethane 107-21-1, Ethylene glycol, reactions 123-08-0, 4-Hydroxybenzaldehyde 141-43-5, Ethanolamine, reactions 1003-29-8, 2-Formylpyrrole 4437-46-1, 1-Phenylhexane-1,4-dione 13676-06-7, Triethyl 2-ethoxyphosphonoacetate 53391-61-0, 2-Methylthiopyrrole 197299-16-4, Ethyl 3-(4-hydroxyphenyl)-2-ethoxypropionate 222555-06-8, Ethyl (S)-3-(4-hydroxyphenyl)-2-ethoxypropionate 267228-43-3, Methyl (S)-3-(4-hydroxyphenyl)-2-methoxypropionate 494852-05-0 494852-06-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 23461-34-9P 50524-76-0P 93617-01-7P 100371-84-4P 321742-49-8P
400715-78-8P 494850-06-5P 494850-07-6P 494850-08-7P 494850-09-8P
494850-10-1P 494850-11-2P 494850-12-3P 494850-13-4P 494850-14-5P
494850-15-6P 494850-16-7P 494850-17-8P 494850-18-9P 494850-19-0P
494850-20-3P 494850-21-4P 494850-22-5P 494850-23-6P 494850-24-7P
494850-25-8P 494850-26-9P 494850-27-0P 494850-28-1P 494850-29-2P
494850-30-5P 494850-31-6P 494850-32-7P 494850-33-8P 494850-34-9P
494850-35-0P 494850-36-1P 494850-37-2P 494850-38-3P 494850-39-4P
494850-40-7P 494850-41-8P 494850-42-9P 494850-43-0P 494850-44-1P
494850-45-2P 494850-46-3P 494850-47-4P 494850-48-5P 494850-49-6P
494850-50-9P 494850-51-0P 494850-52-1P 494850-53-2P 494850-54-3P
494850-55-4P 494850-56-5P 494850-57-6P 494850-58-7P 494850-59-8P
494850-60-1P 494850-61-2P 494850-62-3P 494850-63-4P 494850-65-6P
494850-66-7P 494850-67-8P 494850-68-9P 494850-69-0P 494850-70-3P
494850-71-4P 494850-72-5P 494850-73-6P 494850-74-7P 494850-75-8P
494850-76-9P 494850-77-0P 494850-78-1P 494850-79-2P 494850-80-5P
494850-81-6P 494850-82-7P 494850-83-8P 494850-84-9P 494850-85-0P
494850-86-1P 494850-87-2P 494850-88-3P 494850-89-4P 494850-90-7P

494850-91-8P 494850-92-9P 494850-93-0P 494850-94-1P 494850-95-2P
494850-96-3P 494850-97-4P 494850-98-5P 494850-99-6P 494851-00-2P
494851-01-3P 494851-02-4P 494851-03-5P 494851-04-6P 494851-05-7P
494851-06-8P 494851-07-9P 494851-08-0P 494851-09-1P 494851-10-4P
494851-11-5P 494851-12-6P 494852-04-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT 59-67-6, Nicotinic acid, biological studies 9004-10-8, Insulin, biological studies 11041-12-6, Cholestyramine 23288-49-5, Probucol 50925-79-6, Cholestipol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

IT **494848-08-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of pyrrolylethoxyphenylethoxypropanoates having hypolipidemic and hypocholesteremic activity)

RN 494848-08-7 HCAPLUS
CN Benzenepropanamide, α-ethoxy-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-(2-methyl-5-phenyl-1H-pyrrol-1-yl)ethoxy]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:545659 HCAPLUS
DN 135:137396
TI Preparation of pyrrolylethoxyphenylethoxypropanoates and related compounds for treatment of hyperglycemia, hypertension, cardiovascular disease, and eating disorders.
IN Lohray, Braj Bhushan; Loray, Vidya Bhushan; Barot, Vijay Kumar Gajubhai
PA Cadila Healthcare Ltd., India
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053257	A2	20010726	WO 2001-IN5	20010117
	WO 2001053257	A3	20020627		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2397828	AA	20010726	CA 2001-2397828	20010117
	AU 2001048728	A5	20010731	AU 2001-48728	20010117
	AU 779332	B2	20050120		
	EP 1250323	A2	20021023	EP 2001-921764	20010117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008024	A	20030311	BR 2001-8024	20010117
	JP 2003520268	T2	20030702	JP 2001-553262	20010117
	EE 200200399	A	20031015	EE 2002-399	20010117
	NZ 520402	A	20060428	NZ 2001-520402	20010117
	NO 2002003400	A	20020909	NO 2002-3400	20020715
	BG 106932	A	20040130	BG 2002-106932	20020717
	ZA 2002005789	A	20031002	ZA 2002-5789	20020719
PRAI	IN 2000-MU57	A	20000119		
	WO 2001-IN5	W	20010117		

OS MARPAT 135:137396
GI



I

AB Title compds. [I; R1-R4 = H, halo, perhaloalkyl, OH, SH, amino, NO2, etc.; R2R3 = atoms to form a (substituted) 5-6 membered (heterocyclic) ring; R5, R6 = H, or R5R6 = bond, or R5, R6 = OH, alkyl, alkoxy, halo, acyl, (substituted) aralkyl; X, Y = O, S; R7 = H, perfluoroalkyl, (substituted) alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, alkoxyalkyl, aryloxyalkyl, etc.; W = O, S, NR9; Z = O, NR10; R8 = H, (substituted) alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, hydroxyalkyl, etc.; R9 = alkyl, aryl; R10 = H, (substituted) alkyl, aryl, aralkyl, hydroxyalkyl, aminoalkyl, heteroaryl, etc.; Ar = (substituted) (fused) divalent aryl, heteroaryl, heterocyclyl], were prepared as drugs (no data). Thus, Et 3-(4-hydroxyphenyl)-2-ethoxypropanoate, K2CO3, and DMF were stirred at 70-80° for 10 min. followed by addition of 2-(2,5-dimethyl-1H-pyrrol-1-yl)ethyl methanesulfonate (preparation given) followed by stirring for 5 h at 70-80° and standing overnight to give 89% Et 3-[4-[2-(2,5-dimethylpyrrol-1-yl)ethoxy]phenyl]-2-ethoxypropanoate.

IC C07D207-00
CC 27-10 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1
ST pyrrolylethoxyphenylethoxypropanoate prepn hyperglycemia hypertension cardiovascular disease eating disorder treatment
IT Appetite
(disorder, treatment; preparation of pyrrolylethoxyphenylethoxypropanoates and related compds. for treatment of hyperglycemia, hypertension, cardiovascular disease, and eating disorders)
IT Antidiabetic agents
Antihypertensives
Cardiovascular agents
(preparation of pyrrolylethoxyphenylethoxypropanoates and related compds. for treatment of hyperglycemia, hypertension, cardiovascular disease, and eating disorders)
IT 351426-18-1P 351426-19-2P 351426-20-5P **351426-21-6P**
351426-22-7P 351426-23-8P 351426-24-9P
351426-25-0P 351426-26-1P 351426-27-2P
351426-28-3P 351426-29-4P 351426-30-7P
351426-31-8P 351426-32-9P 351426-33-0P
351426-34-1P 351426-35-2P 351426-36-3P 351426-37-4P
351426-38-5P 351426-39-6P 351426-40-9P **351426-41-0P**
351426-42-1P 351426-43-2P 351426-44-3P
351426-45-4P 351426-46-5P 351426-47-6P
351426-48-7P 351426-49-8P 351426-50-1P 351426-51-2P
351426-52-3P **351426-53-4P 351426-54-5P**
351426-55-6P 351426-56-7P 351426-57-8P
351426-58-9P 351426-59-0P 351426-60-3P
351426-61-4P 351426-62-5P 351426-63-6P
351426-64-7P 351426-65-8P 351426-66-9P
351426-67-0P 351426-68-1P 351426-69-2P 351426-70-5P
351426-71-6P 351426-72-7P 351426-73-8P **351426-74-9P**
351426-75-0P 351426-76-1P 351426-77-2P
351426-78-3P 351426-79-4P 351426-80-7P
351426-81-8P 351427-20-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolylethoxyphenylethoxypropanoates and related compds. for treatment of hyperglycemia, hypertension, cardiovascular disease, and eating disorders)
IT 110-13-4, Hexane-2,5-dione 141-43-5, Ethanolamine, reactions
197299-16-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrrolylethoxyphenylethoxypropanoates and related compds. for treatment of hyperglycemia, hypertension, cardiovascular disease, and eating disorders)
IT 6719-02-4P, 1H-Pyrrole-1-ethanol 83662-06-0P 85801-32-7P
351426-82-9P 351426-83-0P 351426-84-1P 351426-85-2P 351426-86-3P
351426-87-4P 351426-88-5P 351426-89-6P 351426-90-9P 351426-91-0P
351426-92-1P 351426-93-2P 351426-94-3P 351426-95-4P 351426-96-5P
351426-97-6P 351426-98-7P 351426-99-8P 351427-00-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolylethoxyphenylethoxypropanoates and related compds. for treatment of hyperglycemia, hypertension, cardiovascular disease, and eating disorders)
IT **351426-21-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolylethoxyphenylethoxypropanoates and related compds. for treatment of hyperglycemia, hypertension, cardiovascular disease, and eating disorders)

RN 351426-21-6 HCAPLUS

CN Benzenepropanoic acid, 4-[2-(2,5-dimethyl-1H-pyrrol-1-yl)ethoxy]-α-ethoxy-, ethyl ester (9CI) (CA INDEX NAME)



=>